May 2008
Volume 49, Issue 13
ARVO Annual Meeting Abstract  |   May 2008
Rates of Visual Field Progression in Glaucoma Care
Author Affiliations & Notes
  • A. Heijl
    Dept of Clinical Sciences, Ophthalmology, Lund University, Malmo University Hosp, Malmo, Sweden
  • B. Bengtsson
    Dept of Clinical Sciences, Ophthalmology, Lund University, Malmo University Hosp, Malmo, Sweden
  • P. Buchholz
    Allergan Europe, Ettlingen, Germany
  • G. Norrgren
    Allergan Europe, Marlowe, United Kingdom
  • Footnotes
    Commercial Relationships  A. Heijl, Allergan, Carl Zeiss Meditec, Santen, Alcon, F; Allergan, Carl Zeiss Meditec, Alcon, Pfizer, C; B. Bengtsson, Carl Zeiss Meditec, F; Carl Zeiss Meditec, C; P. Buchholz, Allergan, E; G. Norrgren, Allergan, E.
  • Footnotes
    Support  Swedish Medical Research Council K2005-74X-10426-13A, Allergan Inc.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1155. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Heijl, B. Bengtsson, P. Buchholz, G. Norrgren; Rates of Visual Field Progression in Glaucoma Care. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1155. doi:

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine rates of visual field progression (RoP) in manifest open angle glaucoma under ordinary clinical care in a large fairly representative patient material.

Methods: : A majority of diagnosed glaucoma patients in the Malmö metropolitan catchment area receive their primary glaucoma care at the Department of Ophthalmology at Malmö University Hospital. We performed a retrospective chart review including all patients at the department with POAG, NTG and PEX glaucoma with manifest field loss and at least 5 years of follow-up and 5 or more SITA Standard visual field tests during the study period (March 1996 - June 2005), applying minimal exclusion criteria. Rate of visual field progression was determined by a simple linear regression analysis of mean deviation (MD) values over time.

Results: : 583 patients were included, 38% with PEX glaucoma. Mean age at baseline was 71 years, mean follow-up time was 7.8 years, and the mean number of visual fields was 8.9. Mean RoP in the whole cohort was 0.80 dB/year ranging from a maximum progression of 5.58 dB/year to an improvement of 1.24 dB/year. Among all patients 89.4% had negative slopes, and 59.6% of patients had statistically significantly negative slopes (p < 0.05). The distribution of progression rates was negatively skewed and progression rates exceeding 1.5 dB/year were seen in 99 patients (17.0%) and faster than 2.5 dB/year in 26 patients (4.5%).

Conclusions: : Progression rates varied very much between patients in a relatively representative material of patients with open angle glaucoma under conventional clinical care. A great majority of patients had negative slopes. A large minority had progression rates that correspond to a worsening from normal function to blindness in 20 years or less (i.e. > 1.5 dB/year), and a small group progressed at speeds that correspond to progression from normal to blindness in a dozen years or less (i.e. > 2.5 dB/year).

Keywords: visual fields 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.